Navigation Links
AxoGen, Inc. Appoints Shawn McCarrey as Vice President of Sales
Date:3/5/2013

Alachua, FL (PRWEB) March 05, 2013

AxoGen, Inc. (OTCBB: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced today the appointment of Shawn McCarrey to the position of Senior Vice President of Sales, effective immediately. In this role, Mr. McCarrey will participate in the implementation of the Company’s strategic growth initiatives and will lead AxoGen’s sales organization in the United States.

“We are now transitioning into the next phase of the Company’s growth, moving from early adopters to broad usage in surgical peripheral nerve repair,” said Karen Zaderej, Chief Executive Officer of AxoGen. “Shawn’s many years of experience and strong track record of success growing sales of early stage medical technologies will enhance AxoGen’s capabilities and accelerate adoption.    With a strong management team in place and the addition of resources from our recent PDL funding, we are well positioned to drive growth in the peripheral nerve repair market.”
Mr. McCarrey brings to AxoGen more than 15 years of experience as a national medical device sales executive. He most recently served as Executive Vice President of North American Cardiovascular Sales at Bayer Interventional/MEDRAD Interventional. From 1998 through 2009, Mr. McCarrey was rapidly promoted through the executive ranks at Possis Medical, an early commercial stage cardio- and peripheral-vascular company ultimately acquired by MEDRAD Interventional, culminating with his appointment as EVP of Worldwide Sales & Marketing. Earlier in his career, Mr. McCarrey served in sales and sales leadership roles in the Davol and USCI divisions of C.R. Bard.

About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa EMC product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.

To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10497195.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Society for Peripheral Nerve & American Society for Reconstructive Microsurgery 2013 Meetings
2. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at American Association for Hand Surgery 2013 Annual Meeting
3. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
4. U.N. Secretary-General Appoints Ray Chambers as His First Special Envoy for the Financing of the Health-Related Millennium Development Goals
5. Private Real Estate Investment Firm, Cohen Asset Management, Inc., Appoints Senior Vice President of Asset Management for East Coast
6. Dynarex Corporation Appoints a New National Sales Manager to Lead their Sales Organization
7. PaloDEx Appoints Brian Broncatti to the Position of Vice President North America
8. Life Support Technologies Group Appoints Edward Golembe, MD as Co-Clinical Director
9. Life Support Technologies Group Appoints Scott Gorenstein, MD as Co-Clinical Director
10. EPC Group Appoints Industry Veteran to Lead Development Practice Expansion
11. Eagle Village Appoints Mike Mischley and Dani Montini to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/21/2017)... ... August 21, 2017 , ... The Industrial Designers Society of America (IDSA) ... Ceremony and Gala on Aug. 19, 2017 in Atlanta, GA—revealing which 25 designs won ... and rigorous design competitions. See all the winners at http://www.idsa.org/awards/idea/gallery . , “I ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, ... System has assisted multiple clients in successfully passing audits such as Office ... Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with another ... in a research study that focuses on family interactions when dealing with dietary restrictions. ... of adults who have gluten sensitivities who cohabitate with other adults who may or ...
(Date:8/19/2017)... ... August 18, 2017 , ... Western University of Health Sciences will host a ... University’s new Center for Innovation on Wednesday, September 6, 2017. , The symposium will ... followed by a technology exhibition from 1 to 3 p.m. showcasing virtual reality education ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/3/2017)... SAN DIEGO , Aug. 3, 2017  Opioid ... crippling diseases driving up healthcare costs and threatening outcomes, ... the lab supply and IVD industry that support them, ... health care market researcher said that drugs of abuse, ... vendors and sessions at the organization,s 69th meeting in ...
Breaking Medicine Technology: